The University of Hyderabad (UoH) and Krismo Biosciences Private Limited announced a strategic collaboration on Saturday aimed at developing innovative therapies for inflammatory diseases and serious infectious conditions. The biotechnology startup, incubated at ASPIRE-BioNEST, will work with university researchers to create next-generation treatments targeting a range of inflammatory disorders and viral infections.
The partnership will focus significantly on designing antibody-based therapies to combat viral infections including Dengue, COVID-19, and Influenza. Additionally, the collaboration aims to develop treatments for potent toxins produced by harmful bacteria that cause debilitating conditions such as gas gangrene.
According to the agreement, the institutions will collaborate on developing novel therapeutics, conducting preclinical toxicology studies, and performing non-GLP (Good Laboratory Practice) evaluations. The partners also plan to jointly apply for relevant research grants to support their work.
Combining Academic Excellence with Industry Innovation
Professor Nooruddin Khan from UoH's Department of Animal Biology emphasized the unique strengths of the collaboration during the signing ceremony. "This partnership represents the best of both worlds — academic excellence and industry innovation — coming together to address urgent healthcare challenges," he stated.
Dr. Krishna Mohan, CEO of Krismo Biosciences, expressed optimism about the partnership's potential impact, noting that their combined efforts would yield "practical, affordable, and impactful solutions for patients."
The initiative was facilitated by the university's Technology Enabling Centre (UoH-TEC), which was established with support from the Department of Science and Technology (DST), Government of India. This center plays a crucial role in fostering collaborations between academic researchers and industry partners.
Accelerating Translational Research
Professor S. Rajagopal, Project Coordinator of UoH-TEC, highlighted the center's mission in enabling such partnerships. "We are actively encouraging our faculty members to translate their valuable knowledge into tangible technologies and products that can critically address pressing societal needs," he explained.
Rajagopal also expressed gratitude to the DST for recognizing UoH for this important initiative and affirmed UoH-TEC's commitment to connecting academic innovators with established industry partners to bring innovations to market.
The signing ceremony was attended by key figures including Dr. Sunil, Principal Scientific Officer at UoH-TEC, and Dr. Anil Kondreddy, CEO of ASPIRE-BioNEST.
Significance for Medical Innovation in India
This agreement represents a growing trend in India's biomedical research landscape, where academic institutions are increasingly partnering with industry to accelerate the development of medical innovations. Such public-private partnerships are becoming essential drivers in translating laboratory discoveries into clinical applications.
The collaboration between UoH and Krismo Biosciences exemplifies how combining academic research capabilities with industry expertise can potentially address significant unmet medical needs, particularly in the areas of inflammatory disorders and infectious diseases that affect millions globally.
By focusing on both viral infections and bacterial toxins, the partnership aims to develop a diverse portfolio of therapeutic solutions that could significantly impact patient care across multiple disease areas, reinforcing India's growing role in global biomedical innovation.
